Hikma Pharmaceutical USA Inc. v. Amarin Pharma Inc.

Start
​​​​​​​In a unanimous decision of June 4, 2026 in Hikma Pharmaceutical USA Inc. v. Amarin Pharma Inc., authored by Justice Jackson, the Supreme Court clarified the pleading requirements for claims of induced patent infringement when a generic drug manufacturer receives approval to market a drug for a nonpatented use while other uses of the drug remain patented….
By: Ladas & Parry LLP
Previous Story

Supreme Court Finds No Plausible Allegations of Induced Infringement Through Generic Pharmaceutical Manufacturer’s Label and Statements

Next Story

Recent Federal Developments Targeting China-Linked Companies and Overseas Biotechnology Investments and Collaboration